【摘要】：正宮頸癌是我國女性生殖道最常見的惡性腫瘤,一半以上的患者診斷為局部晚期宮頸癌(local-ly advanced cervical cancer,LACC)[1]。國際婦產(chǎn)科聯(lián)盟(FIGO)指定LACC狹義為ⅠB2/ⅡA2期,廣義為ⅠB2~ⅣA期。根治性同步放化療是晚期宮頸癌標(biāo)準(zhǔn)治療,5年生存率約40%[2]。然而,LACC存在預(yù)后較差高危因素,局部病灶難以控制,易發(fā)生遠(yuǎn)處轉(zhuǎn)移,治療效果不滿意,總的5年生存率僅
[Abstract]:Cervical cancer is the most common malignant tumor in female reproductive tract in China. More than half of the patients were diagnosed as locally advanced cervical cancer (local-ly advanced cervical cancer,LACC) [1]. The International Union of Obstetrics and Gynecology (FIGO) designated LACC as stage 鈪，

本文編號：2475761